T hrombospondin (TSP, glycoprotein G, thrombin-sensitive protein) is a large glycoprotein (450 kD) first described in 1971 by Baenziger et al. 1 ' 2 as a secretion product of thrombin-stimulated human platelets. 1 " 4 It is found in the alpha granules of resting platelets 56 and makes up approximately 2% to 4% of total platelet protein 78 and 20% to 30% of released protein. 2 Subsequent work in several laboratories 9 " 11 has revealed that TSP is made up of three probably identical, disutfide-linked monomers organized into a multinodular configuration. A model of the multidomain TSP molecule is shown in Figure 1 . The native three-dimensional structure of TSP is calciumdependent, 12 " 14 as reflected in an increased susceptibility of the protein to proteolysis in the presence of calcium chelators. Thrombospondin does not circulate in appreciable concentrations (~20 ng/ml); 78 ' 15 however, the tissue distribution is broad. Jaffe and collaborators have found that fibroblasts, 16 endothelial cells, 17 and monocytes 18 in culture produce TSP. McPherson et at. 19 also identified TSP in endothelial cells, while Raugi et al. 20 have shown that TSP is produced by aortic smooth muscle cells and fibroblasts. Sage et al. 21 have shown TSP production by Type II alveolar pneumocytes.
synthesis by aortic smooth muscle cells, 26 suggesting that TSP may play a role in the interaction of proliferating cells with the ECM. Atheromatous lesions appear to have an increased amount of TSP compared to non-diseased vessel. 22 ' 27 Like fibronectin and spectrin, TSP can be considered a multifunctional protein; i.e., it is organized into discrete protease-resistant structural domains that can maintain function independent of the rest of the molecule. Among the known functions of TSP are the ability to bind to cellular surfaces (platelet) 28 " 31 and to bind specifically to several macromolecules including heparin, 2 ' 3 fibrinogen, 32 fibronectin, 3334 plasminogen, 35 histidine-rich glycoprotein, 36 thrombin, 37 and Type V collagen. 38 In addition to its interaction with fibrinogen, TSP also interacts with fibrin. 39^41 It is incorporated into fibrin clots and modulates the structure of the formed clot. TSP also has hemaggluinating activity 42 and plays an important role in platelet aggregation, 43 stabilizing fibrinogen binding to the activated platelet surface and thereby strengthening interplatelet interactions. Currently, considerable work is being done to characterize the separate functional domains of the TSP molecule. The best characterized domain is the 23-35 kD N-terminal heparin-binding fragment 10 that has been isolated by Dixit et al. 45 and Raugi et al. 46 Fibrinogen binding 47 245 tinating domains 48 have also been partially characterized, as has a fragment important for platelet aggregation. 49 ' M The latter appears to be near or at the carboxy-terminal region of the molecule. 50 This review will focus on the role of TSP in platelet aggregation and the ability of TSP to serve as a surface for macromolecular assembly on cell surfaces and in extracellular environments.
Role of Thrombospondin in Platelet Aggregation
Platelet aggregation is a crucial step in normal hemostasis. Endothelial denudation leads rapidly to platelet adhesion, degranulation, and recruitment of additional platelets and eventually results in the formation of a hemostatic plug. From an operational point of view, as deliniated by aggregometer studies, platelet aggregation can be viewed as occurring in two phases. After stimulation with a variety of physiological stimuli (e.g., ADP, epinephrine, thrombin, or collagen), platelets undergo shape change with pseudopod formation and initiate the primary reversible phase of aggregation. With a strong stimulus, platelet secretion takes place, with the release of platelet a-granule proteins and recruitment of additional platelets, giving rise to the secondary irreversible phase of aggregation. The molecular events leading to primary aggregation have been well characterized 51 " 55 and include the binding of fibrinogen to the platelet membrane glycoprotein llb/llla (GPIIb/llla) complex and clustering of the GPIIb/llla fibrinogen receptor into "patches" on the platelet surface. 56 ' 57 Fibrinogen is bivalent with respect to platelet binding, resulting in the formation of interplatelet bridges and thus aggregation:
The molecular events responsible for the secondary, irreversible phase of aggregation are less well understood. This phase is secretion-dependent and probably mediated in part by the four major adhesive glycoproteins of the platelet alpha granule, fibrinogen, fibronectin, von Willebrand factor (vWF) and TSP, which when released during aggregation achieve high local concentrations in the microenvironment of the developing platelet plug. There is considerable evidence that TSP may play a major role in the secondary, irreversible phase of aggregation. This evidence, which is reviewed below is based on three experimental observations: 1) TSP binds to the activated platelet surface 28 " 31 and coclusters with fibrinogen and GP lib/ Ilia; 57 2) TSP is the endogenous platelet lectin; 42 and 3) anti-TSP antibodies inhibit platelet aggregation. 43
Thrombospondin Binds to the Activated Platelet Surface
Phillips et al. 28 and George et al. 4 showed that TSP released from platelets after thrombin stimulation bound rapidly (in less than 1 min) to the platelet surface in the presence of calcium. Immunocytochemical studies have since confirmed the localization of TSP to the a-granules of resting platelets with subsequent surface association after stimulation. 57 -59 Ginsberg et al. 31 and Plow et al. 30 using 125 I-TSP have demonstrated saturable, high affinity, calcium-dependent binding of exogenous TSP to the surface of thrombin-stimulated platelets. The binding of TSP, like that of the other three a-granule adhesive glycoproteins, was inhibited by monoclonal antibodies (T10 and 10E5) to the GPIIb/llla complex, 60 suggesting a common binding mechanism. They and others, however, have shown that thrombin stimulated thrombasthenic platelets (which are deficient in GPIIb/llla and do not bind fibrinogen) bound equivalent amounts of TSP to normal platelets, 30 ' M suggesting a platelet-binding site for TSP independent from GPIIb/llla and fibrinogen. Using a sensitive ELISA binding assay, we also have shown that the binding sites of fibrinogen for TSP were different from those for GPIIb/llla. 32 In addition to the binding of TSP to thrombin-stimulated platelets, there appears to be a smaller number of binding sites (~310O/platelet) on resting platelets for TSP. 31 This interaction was not calcium-dependent and not inhibited by antibodies to GPIIb/ Ilia.
Studies from our group using frozen thin-section electron microscopy and colloidal gold-labeled immune probes have shown that TSP and fibrinogen co-localize in patches on the stimulated platelet surface 57 ( Figure 2 ) in association with GPIIb/llla. Thus, during platelet activation, a macromolecular assembly of TSP and fibrinogen occurs in proximity to the GPIIb/llla complex. Identification of the putative platelet TSP receptor as well as the relationship of released vWF and fibronectin to this assembled membrane "patch" remains to be determined.
Thrombospondin, the Endogenous Platelet Lectin
One reflection of the altered membrane state of thrombin or ionophore-stimulated platelets is the development of a membrane-bound "lectin"-like activity capable of agglutinating fixed, trypsinized RBC and fixed platelets. 81 The platelet lectin seems to be important in mediating aggregation 62 by binding to fibrinogen 63 on adjacent platelets. Aminosugars and oligoamines that inhibit the lectin activity also inhibit aggregation, 64 further suggesting a role in normal aggregation, although these amines also inhibit the binding of fibrinogen to purified platelet glycoproteins lib/ Ilia. 65 This lectin activity has been extensively studied by Gartner and colleagues 66 and has been found to be secretion-dependent, due to an a-granule component and normal in thrombasthenic platelets. Jaffe et al. 42 have demonstrated that purified TSP has similar hemagglutinating activity to the platelet lectin and that TSP blocks the hemagglutinating activity of fixed, thrombin-stimulated platelets, thus showing that TSP is the endogenous platelet lectin. This has been confirmed by others, who have shown that polyclonal 67 and monoclonal 68 antibodies to TSP can inhibit the platelet-lectin activity. These antibodies also inhibit platelet aggregation.
Antibodies to Thrombospondin Inhibit Platelet Aggregation
The demonstration that TSP binds to both fibrinogen and to the activated platelet surface and co-localizes with GPIIb/llla, along with the identification of TSP as the endogenous platelet lectin, suggests a role for TSP in normal aggregation. To clarify this role, Leung 43 has studied the effect of monospecific, affinity-purified, anti-TSP Fab on platelet aggregation and fibrinogen binding. Anti-TSP Fab #.* Figure 2 . Topographical distribution of thrombospondin (TSP), fibrinogen, and glycoprotein Ilia. A. Thrombin-stimulated platelet sections incubated with a goat antifibrinogen antibody conjugated with small gold particles (10 nm) and a rabbit anti-TSP antibody followed by a goat antirabbit antibody conjugated with large gold particles (30 nm). After stimulation, co-clusters of the TSP (small gold) and fibrinogen (large gold) probes are seen on the platelet surface, x 63,000. B. Thrombin-stimulated platelet sections treated as in A except that monoclonal anti-GPIIIa antibody followed by goat antimouse antibody conjugated with small gold particles was substituted for the antifibnnogen. Coclusters of the TSP (small gold) and GPIIIa (large gold) probes are seen covering a platelet pseudopod. x 63,000. Bar = 100 nm. partially inhibited aggregation of gel-filtered human platelets ( Figure 3 ) when stimulated with thrombin, collagen, or ADP. The inhibition was not due to inhibition of secretion and was associated with a decrease in the size of platelet aggregates (increased number of microaggregates and decreased number of macroaggregates). Anti-TSP did not inhibit the initial phase of ADP-induced platelet aggregation (and did not inhibit indomethacin-treated platelets) but caused a rapid disaggregation of the primary phase and abolition of the secondary phase of aggregation. This data suggests that the inhibitory effect was directed at the secretion-dependent phase of platelet aggregation. In addition, anti-TSP inhibited specific binding of 12S l-fibrinogen to thrombin-stimulated platelets, causing a marked decrease in the affinity of fibrinogen for its receptor on the platelet surface ( Figure 4 ). Kinetic analysis of the binding data revealed that the major effect was due to an increase in offrate; i.e., fibrinogen binding was less stable in the presence of anti-TSP.
The ability of anti-TSP antibodies to inhibit platelet aggregation has been confirmed by several investigators using both monoclonal 89 and polyclonal 49 ' n -71 antibodies. It appears that a carboxy-terminal 18kD TSP fragment may be involved in mediating the effect of TSP on platelet aggregation. 50 We have proposed that platelet aggregation is a dynamic, sequential multistep process, governed initially by the interaction of fibrinogen with platelet GPIIb/llla. The plate- let-TSP-fibrinogen interaction then participates in the evolution of an inital reversible microaggregate to an irreversible macroaggregate. A hypothetical model illustrating the molecular events taking place on the membrane during the secondary phase of platelet aggregatin is shown in Figure  5 . The bridging fibrinogen moleculae linking GPIIb/llla receptor sites on adjacent platelets is reinforced by the attachment of TSP leading to the irreversible state. This model is also consistent with the observation that Glanzmann's thrombasthenic platelets, which are deficient in GPIIb/llla but have intact a-granule proteins, including TSP, are completely defective in platelet aggregation, while Grey platelets, which are deficient in a-granules, have suboptimal aggregation. In addition to TSP and fibrinogen, thrombin stimulation leads to specific expression and binding of vWF, fibronectin (FN), and platelet factor 4 (PF4) on the activated platelet surface. 60 The above model does not preclude the participation of these a-granule proteins in the platelet aggregation stabilization process; the role of these proteins in platelet aggregation is currently understudy in several laboratories. Recently a monoclonal anti-FN antibody inhibitory to platelet aggregation has been described by Dixit et al. 72 The macromolecular assembly of llb/llla, fibrinogen, TSP, and perhaps FN on the activated platelet surface has lead us to hypothesize that TSP with its remarkable ability to bind a multitude of different macromolecules may serve in other microenvironments as a focus for the assembly of other multimolecular complexes. We have found, for example, that TSP can form separate trimolecular complexes with histidine-rich glycoprotein (HRGP) and plasminogen (Pig) 73 and with Pig and tissue plasminogen activator (TPA) 74 and we have speculated on the potential biological function of such complexes. Such multimolecular complexes could serve important regulatory functions, for example by increasing local concentrations of biologically active substances, providing protection from inhibitors, or facilitating the interaction between bound substances. The remainder of this review will focus on such multimolecular complex formation.
Thrombospondln-Hlstldlne-Rlch Glycoprotein-Plasmlnogen Interactions
HRGP is a platelet a-granule protein 75 functions. HRGP interacts with the high affinity lysine-binding site of Pig, 77 which mediates the binding of plasmin(ogen) to fibrin and to a 2 -plasmin inhibitor. By reducing the binding of Pig to fibrin, HRGP may represent a physiological counterpart of the antifibrinolytic amino acids (e.g., eamino-n-caproicacid, EACA). HRGP also interacts strongly with heparin, 78 ' re resulting in the neutralization of its anticoagulant activity, and may therefore play a role in modulating the anticoagulant properties of heparin in plasma. HRGP also interacts with several divalent metals 80 and is immunochemically identical with a serum factor that inhibits autorosette formation between erythrocytes and peripheral lymphocytes, 81 suggetjng that it may play a role in metal homeostasis and in the regulation of the immune response.
We have found, using monospecific antibodies in an ELISA binding assay, that purified human TSP adsorbed passively to polystyrene microtiter wells bound spcifically and saturably with high affinity to HRGP 36 and to Pig. 35 The TSP-HRGP complex formation was also demonstrated in the fluid phase using sucrose density ultracentrifugation, revealing a stoichiometric relationship of 1 mol TSP per 3.5 mol HRGP. TSP-PIg complex formation was confirmed with both an affinity bead assay (using Sepharose-linked TSP and 1Z5 l-Plg) and a rocket immunoelectrophoresis assay in which a 1Z5 l-TSP-Plg complex was immunoprecipitated in agar by anti-Pig antiserum. The interaction of Pig with TSP, like that with fibrin, is mediated by the Pig high affinity lysine binding site. TSP also complexed with plasmin, but did not inhibit its amidolytic or fibrinolytic activity.
We have recently demonstrated that TSP can form trimolecular complexes containing both HRGP and Pig. 73 When HRGP and Pig were incubated together in TSPcoated ELISA wells and the binding of each ligand was measured immunologically in parallel wells, both proteins could be detected on TSP (Figure 6 ). TSP-PIg binding was not inhibited by fluid HRGP and TSP-HRGP binding was not inhibited by fluid Pig, suggesting independent binding sites on TSP for the two proteins. Also, while Pig binding was inhibited by EACA, HRGP binding was not effected. Trimolecular complex formation was also shown by rocket immunoelectrophoresis, a system independent of the possible artefactual effect of plastic. Pig mxed with TSP and electrophoresed into anti-Pig containing agar migrated more rapidly than the same amount of Pig alone and formed an anodally moving sharp peak that contained both proteins. When HRGP was included in the TSP-PIg mixture, a similar rapidly moving arc formed. To demonstrate that this immunoprecipitin arc contained the individual components of the trimolecular complex, studies were performed in which each of the ligands was separately radiolabeled. Figure 7 shows an autoradiograph of such a gel; each of the three wells contained the same molar ratio of TSP/HRGP/PIg (1:3:3), but in each well a different ligand was labeled. All three arcs were radioactive, demonstrating that all three proteins (a trimolecular complex) were immunopredpitated by the anti-Pig. TSP or HRGP alone or the TSP-HRGP complex as expected was not precipitated.
The biological significance of these interactions is unknown. The TSP-HRGP complex and the trimolecular complex, however, retained the heparin binding and neutralizing function of HRGP in plasma, 38 while the TSP-PIg complex inhibited TPA-induced fibrinolysis. 35 When incubated with Pig before addition to 125 l-fibrin plates, TSP significantly inhibited the generation of plasmin activity by TPA. Analysis by Michaelis-Menten kinetics showed that TSP acted primarily as a noncompetitive inhibitor; i.e., by decreasing the effective enzyme (TPA) concentration. 
Thrombospondin-Plasmlnogen-Tissue Plasmlnogen Activator Interactions
The kinetic observation that TSP is a noncompetitive inhibitor of Pig activation by TPA in a fibrin milieu suggests that a TSP-Plg-TPA ternary complex may form as an alternative to a fibrin-Plg-TPA complex. It is possible that such complex formation in microenvironments lacking fibrin may play a role in modulating plasmin generation. Such nonfibrin-related plasmin generation may have important biological implications in such physiological and pathological processes as inflammation, 82 tumor cell implantation and migration, 83 embryogenesis, 84 ovulation, 85 prohormone to hormone conversion, 86 and neurodevelopment. 87 Reich 88 and others have postulated that plasmin generation by TPA from Pig may be a major mechanism for facilitating cell migration through normal tissue boundaries. Since Pig activation by TPA in the fluid phase, however, is kinetically highly unfavorable, 89 other mechanisms in microenvironments lacking fibrin must exist to facilitate efficient activation.
We have directly demonstrated the TSP-Plg-TPA ternary complex formation by ELISA and affinity bead binding studies using either monospecific anti-TPA or 12S I-TPA. 74 TPA bound minimally to TSP alone, but when Pig was first immobilized on surface bound TSP, TPA bound specifically and with high affinity (H^-12-36 nM) to the TSP-PIg complexes (Figure 8 ). As with the TSP-Plg-HRGP com- plex, the trimolecular complex formation was confirmed by rocket immunoelectrophoresis. To study the effect of such interactions on plasmin generation in the absence of fibrin, we undertook kinetic analysis of Pig activation by TPA in the presence of insolubilized TSP using a fluorogenic plasmin substrate (D-val-leu-lys-AFC). Activation followed Michaelis-Menten kinetics and was markedly enhanced compared to activation in fluid phase or in the presence of insolubilized control proteins (FN or vWF). The major effect as shown in Table 1 tion of enzyme may be required for effective fibrinolysis. The activation of Pig on a TSP surface by TPA, such as might take place in an extravascular inflammatory site, occurs at an intermediate level of efficiency which may be more appropriate for pathophysiological events related to cell migration, tissue remodeling, or both. The role of these complicated macromolecular interactions in Pig activation in nonfibrin-containing extravascular settings remains to be determined. It is of interest, however, that TSP is an important constituent of the extracellular matrix. It has recently been shown that plasmin generation in the ECM of alveolar macrophages is a rate-limiting determinant of proteolysis of nonfibrinous structural protein. 90 TSP and HRGP are synthesized by monocytesmacrophages and are also both secreted by activated platelets and thus may be geographically positioned to bind Pig in various extravascular sites and thereby modulate local proteolysis.
Conclusions
Thrombospondin is a versatile multifunctional glycoprotein with a widespread and apparently highly regulated tissue distribution. By virtue of its remarkable affinity for multiple macromolecules, it can serve as a focus for macromolecular assembly of multiprotein complexes. An important biological role for one such complex (TSP-fibrinogen-platelet surface) in stabilizing platelet aggregation has been firmly established. The role of other TSP-containing complexes remains to be determined and is currently under study in several laboratories.
